Alopexx Expands Leadership Team with Appointment of Thomas T. Thomas as Chief Financial Officer

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Oct. 20, 2021 /PRNewswire/ — Alopexx, Inc. a clinical stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal and parasitic infections, today announced that Thomas T. Thomas has joined the Company as chief financial officer. Mr. Thomas has over 30 years of experience in financial management and entrepreneurship in biotechnology, packaged goods, financial services and non-profit organizations.
Click here to view original post